Previous close | 61.00 |
Open | N/A |
Bid | 87.00 |
Ask | 95.80 |
Strike | 160.00 |
Expiry date | 2025-06-20 |
Day's range | 61.00 - 65.00 |
Contract range | N/A |
Volume | |
Open interest | 6 |
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.